Amgen receives summary judgement ruling in Ariad case
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticalssaid that it plans to pursue “appropriate legal action to obtain a review of the rulings” after a federal judge in the US District Court for the District of Delaware ruled against it in a patent dispute withAmgen.